Gland Pharma Limited (NSE: GLAND) reported Revenue from Operations of ₹938.28 Crore down from ₹1,063.32 Crore year on year, a decline of 11.8%. Consolidated Net Profit of ₹231.94 Crore, slumped 15% from ₹273 Crore in the same quarter of the previous year. The Earnings per Share is ₹14.08 for this quarter.
Gland Pharma Limited Q3 FY23; Net Profit Down To 232 Crore
Related Post
- Pyramid Technoplast Limited reports Q3 FY26 volume-led growth; margins steady as new capacities ramp up
Pyramid Technoplast Limited (NSE: PYRAMID, BSE: 543969) reported moderate revenue growth in the December quarter,…
-
Dilip Buildcon Limited (NSE: DBL, BSE: 540047) reports Q3 FY26 results as order book hits record high
Dilip Buildcon Limited (NSE: DBL, BSE: 540047) reported its financial results for the quarter and…
-
Edelweiss Financial Services Limited charts multi-year growth across asset management and insurance businesses
Edelweiss Financial Services Limited (NSE: EDELWEISS, BSE: 532922) presented a multi-year snapshot of growth across…